View Item 

Show simple item record

Impact of Cytomegalovirus Disease in D+/R– Kidney Transplant Patients Receiving 6 Months Low‐Dose Valganciclovir Prophylaxis
dc.contributor.authorLuan, Fu Len_US
dc.contributor.authorKommareddi, Mallikaen_US
dc.contributor.authorOjo, Akinlolu O.en_US
dc.date.accessioned2011-11-10T15:38:05Z
dc.date.available2012-11-02T18:56:47Zen_US
dc.date.issued2011-09en_US
dc.identifier.citationLuan, F. L.; Kommareddi, M.; Ojo, A. O. (2011). "Impact of Cytomegalovirus Disease in D+/R– Kidney Transplant Patients Receiving 6 Months Low‐Dose Valganciclovir Prophylaxis." American Journal of Transplantation 11(9). <http://hdl.handle.net/2027.42/87092>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87092
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCytomegalovirusen_US
dc.subject.otherD+/R–en_US
dc.subject.otherGraft Lossen_US
dc.subject.otherLate‐Onseten_US
dc.subject.otherProphylaxisen_US
dc.subject.otherValgancicloviren_US
dc.titleImpact of Cytomegalovirus Disease in D+/R– Kidney Transplant Patients Receiving 6 Months Low‐Dose Valganciclovir Prophylaxisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumInternal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MIen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87092/1/j.1600-6143.2011.03611.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2011.03611.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferencePaya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611 – 620.en_US
dc.identifier.citedreferenceCytomegalovirus. Am J Transplant 2004; 4 ( Suppl 10 ): 51 – 58.en_US
dc.identifier.citedreferencePreiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218 – 227.en_US
dc.identifier.citedreferenceHumar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high‐risk kidney transplant recipients. Am J Transplant 2010; 10: 1228 – 1237.en_US
dc.identifier.citedreferenceAbbott KC, Hypolite IO, Viola R, et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402 – 409.en_US
dc.identifier.citedreferenceSagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long‐term recipient and kidney graft survival. Kidney Int 2004; 66: 329 – 337.en_US
dc.identifier.citedreferenceArthurs SK, Eid AJ, Pedersen RA, et al. Delayed‐onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840 – 846.en_US
dc.identifier.citedreferenceAsberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106 – 2113.en_US
dc.identifier.citedreferenceHelantera I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 2010; 10: 2026 – 2032.en_US
dc.identifier.citedreferenceHumar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R– kidney transplant recipients is associated with long‐term reduction in cytomegalovirus disease: Two‐year results of the IMPACT study. Transplantation 2010; 90: 1427 – 1431.en_US
dc.identifier.citedreferenceAkalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high‐risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731 – 735.en_US
dc.identifier.citedreferenceGabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low‐dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single‐center, retrospective analysis. Pharmacotherapy 2004; 24: 1323 – 1330.en_US
dc.identifier.citedreferenceLuan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six‐month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449 – 2458.en_US
dc.identifier.citedreferenceWeng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low‐dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83: 290 – 296.en_US
dc.identifier.citedreferenceAkalin E, Bromberg JS, Sehgal V, Ames S, Murphy B. Decreased incidence of cytomegalovirus infection in thymoglobulin‐treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004; 4: 148 – 149.en_US
dc.identifier.citedreferenceKalil AC, Mindru C, Florescu DF. Effectiveness of Valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: Direct and indirect treatment comparison meta‐analysis. Clin Infect Dis 2011; 52: 313 – 321.en_US
dc.identifier.citedreferenceVolinsky CT, Raftery AE. Bayesian information criterion for censored survival models. Biometrics 2000; 56: 256 – 262.en_US
dc.identifier.citedreferenceReischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69 – 77.en_US
dc.identifier.citedreferenceSagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850 – 856.en_US
dc.identifier.citedreferenceKliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long‐term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975 – 983.en_US
dc.identifier.citedreferenceHodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008 ( 2 ); CD003774.en_US
dc.identifier.citedreferenceKalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta‐analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870 – 880.en_US
dc.identifier.citedreferenceOpelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928 – 936.en_US
dc.identifier.citedreferenceKotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779 – 795.en_US
dc.identifier.citedreferenceHumar AL, Vicenti, Y, Blumberg F, et al. Long term results of the IMPACT study: 200 vs 100 days of valganciclovir prophylaxis in kidney recipients. Am J Transplant 2010; 10 ( Suppl 4 ): 143 – 144.en_US
dc.identifier.citedreferenceKalil AC, Sun J, Florescu DF. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am J Transplant 2011; 11: 18 – 21.en_US
dc.identifier.citedreferenceChamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008; 8: 1297 – 1302.en_US
dc.identifier.citedreferenceKDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 ( Suppl 3 ): S46 – S48.en_US
dc.identifier.citedreferenceUS Oragn Procurement and Transplantation Network, the Scientific Registry of Transplant Recipients. 2008 Annual Report, Transplant Data 1994–2007. In: Department of Health and Human Service, Human Resource and Service Administration, Healthcare System Bureau, Division of Transplantation, United Network for Organ Sharing, Arbor Research Collaborative for Health, eds. Ann Arbor, MI: Author; 2008.en_US
dc.identifier.citedreferenceSan Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 ( 7 ): 875 – 882.en_US
dc.identifier.citedreferenceMourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus‐based immunosuppression. Transplantation 2001; 72: 1050 – 1055.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2011.03611.x.pdf
Size:
184.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.